MULTIPLE-FIELD INTERSTITIAL PHOTODYNAMIC THERAPY OF SUBCUTANEOUSLY TRANSPLANTED CHOLANGIOCELLULAR CARCINOMA RS-1 IN RATS

D.A. Tzerkovsky*
N.N. Alexandrov National Cancer Center of Belarus, Lesnoy 223040, Republic of Belarus

The aim of present study was to investigate an antitumor efficacy of multiple-field interstitial photodynamic therapy (iPDT) in vivo. Materials and Methods: The study was performed on 15 white random-bred rats with subcutaneously transplanted cholangiocellular carcinoma RS-1. Chlorine-based photosensitizer (PS) Ce6CPPPS was administered via single injection at a dose of 2.5 mg/kg into the animal’s caudal vein. Photoirradiation (PI) of tumors was carried out 3 h after PS administration using 7 optical fibers SMA-905 with diode laser with 660 ± 5 nm wavelength at exposure doses of 150 and 300 J/cm² with 0.21 W/cm² fluency rate. The total power density was 360 mW and treatment time was 12 and 24 min. Antitumor efficacy of iPDT was assessed by evaluation of necrosis areas and depth of necrosis in experimental tumors. Results: The results have shown that interstitial PI with multi-field low power density enhanced the antitumor effect of PDT in the RS-1 model. Necrosis areas in tumor tissues after PI with exposure doses 150 and 300 J/cm² 24 h and 96 h after treatment were 83.78 ± 4.25 and 100% (p = 0.00074); 56.79 ± 3.24 and 95.46 ± 1.64% (p < 0.00001), respectively. Conclusion: An analysis of the literature data and the results obtained in this study evidence on high effectiveness of the method of multiple-field. Key Words: multiple-field interstitial photodynamic therapy, photosensitizer, cholangiocellular carcinoma.

Photodynamic therapy (PDT) is a modern and highly effective option in the treatment of malignant tumors of the skin, lung, bladder, brain, pancreas and other localizations [1–3]. PDT is a treatment method based on the significant increase of the cytotoxicity of drugs with photoirradiation (PI) of the tumor tissue. According to numerous studies, photochemical reactions include a direct interaction of excited molecules with the help of PI, photosensitizer (PS) on the substrate and forming transient radicals that react with oxygen. Interaction initiates a cascade of free radicals, such as singlet oxygen (1O₂), hydroxyl radical (OH), hydrogen peroxide (H₂O₂) and superoxide anion radical (O₂⁻), causing the development of oxidative stress syndrome. As a result, PDT effectively induces tumor-cell apoptosis and necrosis (Necr). The two possible mechanisms might be: a) promoting mitochondria to release cytochrome C and activate caspase-3, then to initiate apoptosis; b) destroying microvessels, inhibition of angiogenesis and the induction of ischemia and anoxia of tumor cells, resulting in ischemic Necr [2, 4, 5].

PDT has rarely been used clinically in the treatment of liver tumors, mainly because of effective accumulation of PS in liver tissue [6, 7]. Distribution studies show that PS are accumulated in high amounts in reticuloendothelial tissue, such as liver, spleen, and kidney, and in particular, liver tissue contains high PS levels after its administration [8, 9]. Therefore, superficial tumor PI causes substantial liver Necr. The limited light penetration during superficial illumination makes it impossible to treat deep-seated or larger solid tumors. In order to prevent possible complications, research teams recommended the use of an interstitial type of PI of liver tumors.

Submitted: March 03, 2017.
*Correspondence: E-mail: tzerkovsky@mail.ru
Abbreviations used: iPDT — interstitial photodynamic therapy; mTHPC — meta-tetra(hydroxyphenyl)chlorine; Necr — necrosis; PDT — photodynamic therapy; PI — photoirradiation; PS — photosensitizer.
**Photosensitizer.** Chlorin e6 conjugated with polyvinyl pyrrolidone (Ce6CPPPS) produced by Scientific Pharmaceutical Center of RUE “Belmedpreparaty”, Minsk, Republic of Belarus) was injected into the tail vein at a standard dose of 2.5 mg/kg.

**Interstitial photodynamic therapy.** PI of tumors was carried out 3 h after PS administration using diode laser with 660 ± 5 nm wavelength (“PDT Diode laser”, Minsk, Republic Belarus) at exposure doses of 150 and 300 J/cm² with 0.21 W/cm² fluency rate. The total power density was 360 mW and treatment time was 12 and 24 min. 7 optical fibers SMA-905 (“Fotonika Plus”, Ukraine) for PI were introduced into the tumor at a distance of 1 cm from each other at a depth of 1–1.5 cm (Fig. 1).

The distribution of the total power density for each fiber is shown in Table 1 and Fig. 2.

**Table 1.** Distribution of the total power density (P = 360 mW) to optical fibers

<table>
<thead>
<tr>
<th>Optical fiber No.</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Power density, mW</td>
<td>43.2</td>
<td>36.0</td>
<td>50.4</td>
<td>99.4</td>
<td>43.2</td>
<td>42.4</td>
<td>45.4</td>
</tr>
<tr>
<td>Power density, %</td>
<td>12.0</td>
<td>10.0</td>
<td>14.0</td>
<td>27.6</td>
<td>12.0</td>
<td>11.8</td>
<td>12.6</td>
</tr>
</tbody>
</table>

Antitumor efficacy was evaluated 24 and 96 h after the treatment by quantification of RS-1 tumor necrosis area (NecrA) by vital staining of tumor bearing animals with 0.6% Evans blue solution. The animals were sacrificed by chloroform; the tumors were removed, fixed in 10% formalin solution and frozen. Transverse tumor sections 2–3 mm thick were made. NecrA due to direct effect on tumor cells or structural and functional disorders in microcirculation remained unstained. The percentage of tumor necrotic unstained parts was evaluated using “ImageJ” (NIH, Bethesda, USA).

**Statistical processing of the results.** The values obtained were processed using standard statistical methods of Origin Stat 7.0 software. Statistical significance of differences was relevant at $p < 0.05$.

**RESULTS**

**Early post-treatment changes.** In the study, the sensitivity of subcutaneously implanted RS-1 to iPDT was investigated. According to our findings, all animals subjected to iPDT at an exposure dose 300 J/cm² presented the necrotic changes of maximal size (100%). In the control group, this index showing the emergence of spontaneous central Necr was insignificant (14.88 ± 4.33%). Post-treatment necrotic changes after iPDT were assessed using the vital staining technique with Evans blue. Fig. 3 shows the data on NecrA in histotopographic sections of RS-1 in untreated control and 24 h after iPDT at the exposure doses of 150 and 300 J/cm².

Fig. 4 shows the data on NecrA in histotopographic sections of RS-1 in untreated control and 96 h after iPDT at the exposure doses of 150 and 300 J/cm².

Percentage of Necr in groups of animals treated with iPDT at the exposure doses of 150 and 300 J/cm² 24 and 96 h after treatment is shown in Table 2.

Depth of tumor Necr in groups of animals treated with iPDT at exposure doses of 150 and 300 J/cm² 24 and 96 h after treatment is shown in Table 3.
Table 2. NecrA in histotopographic sections of subcutaneously transplanted RS-1 tumor of rats after treatment

<table>
<thead>
<tr>
<th>Groups</th>
<th>Number of sections, n</th>
<th>Mean tumors area (Sc), cm²</th>
<th>NecrA (Sн), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>16</td>
<td>[min = 6.43; max = 14.32]</td>
<td>14.88 ± 4.33</td>
</tr>
<tr>
<td>iPDT* 150 J/cm²</td>
<td>16</td>
<td>[min = 9.33; max = 20.81]</td>
<td>83.78 ± 4.25</td>
</tr>
<tr>
<td>iPDT* 300 J/cm²</td>
<td>14</td>
<td>[min = 5.39; max = 11.33]</td>
<td>0.11</td>
</tr>
<tr>
<td>iPDT** 150 J/cm²</td>
<td>15</td>
<td>[min = 5.81; max = 13.61]</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>iPDT** 300 J/cm²</td>
<td>15</td>
<td>[min = 6.96; max = 22.39]</td>
<td>&lt; 0.00001</td>
</tr>
</tbody>
</table>

Note: Tables 2 and 3: *NecrA in the tumor was evaluated 24 h after iPDT. **NecrA in the tumor was evaluated 96 h after iPDT. *Sc iPDT 150 J/cm² 24 h vs Sc iPDT 150 J/cm² 96 h, p = 0.0018; Sc iPDT 300 J/cm² 24 h vs Sc iPDT 300 J/cm² 24 h, p = 0.0015; Sc iPDT 150 J/cm² 96 h vs Sc iPDT 300 J/cm² 96 h, p = 0.015. #Sc iPDT 150 J/cm² 24 h vs Sc iPDT 150 J/cm² 24 h, p = 0.00002; Sc iPDT 300 J/cm² 4 h vs Sc iPDT 300 J/cm² 96 h, p = 0.01; Sc iPDT 150 J/cm² 24 h vs Sc iPDT 300 J/cm² 24 h, p = 0.00074; Sc iPDT 150 J/cm² 96 h vs Sc iPDT 300 J/cm² 96 h, p < 0.00001.

Table 3. Depth of Necr in histotopographic sections of subcutaneously transplanted RS-1 tumor of rats after treatment

<table>
<thead>
<tr>
<th>Groups</th>
<th>Number of sections, n</th>
<th>Depth of tumor Necr (L), cm</th>
<th>Mean NecrA (Sн), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>16</td>
<td>14.88 ± 4.33</td>
<td>14.88 ± 4.33</td>
</tr>
<tr>
<td>iPD T* 150 J/cm²</td>
<td>16</td>
<td>2.69 ± 0.16</td>
<td>83.78 ± 4.25</td>
</tr>
<tr>
<td>iPDT* 300 J/cm²</td>
<td>14</td>
<td>2.39 ± 0.11</td>
<td>[min = 53.46; max = 100]</td>
</tr>
<tr>
<td>iPDT** 150 J/cm²</td>
<td>15</td>
<td>2.15 ± 0.11</td>
<td>56.79 ± 3.24</td>
</tr>
<tr>
<td>iPDT** 300 J/cm²</td>
<td>15</td>
<td>2.84 ± 0.15</td>
<td>95.46 ± 1.64</td>
</tr>
</tbody>
</table>

Note: *L iPDT 150 J/cm² 24 h vs L iPDT 150 J/cm² 96 h, p = 0.009; L iPDT 300 J/cm² 24 h vs L iPDT 300 J/cm² 96 h, p = 0.022.

The results obtained suggest that iPDT with multi-field low power density PI enhances the effect on the RS-1 rats tumor model. The use of exposure dose of 300 J/cm² significantly increases NecrA in tumor tissues compared with 150 J/cm² 24 h (p = 0.00074) and 96 h (p < 0.00001).

DISCUSSION

Malignant primary and metastatic liver tumors are a serious problem for modern oncology. The main treatment for this type of tumors is surgical removal and chemotherapy. In spite of obvious achievements of the medical science of the last decades, the results of treatment of patients with liver tumors remain disappointing. With poor prognosis, development of new therapeutic modalities is desirable, especially for patients with non-resectable, non-transplantable, or recurrent liver tumors. Local tumor ablation therapies such as radiofrequency ablation, ethanol injection, cryotherapy, and PDT are potentially useful palliative approaches. iPDT is an effective and promising method of treatment of liver tumors.

At the moment, we found only a few articles, confirming the effectiveness of iPDT in the treatment of primary and metastatic liver tumors in laboratory animals [13, 14]. Experimental studies, using hematoporphyrin derivative and photofrin, have shown iPDT to be capable of inducing tumor destruction within the liver, despite limitations like non-selective uptake and limited light penetration [13]. van Hillegersberg et al. [13] reported about high antitumor efficacy of iPDT (λ = 625 nm; 200 mW/cm²; 100–1600 J) with intravenously administered photofrin at a dose of 5 mg/kg in the treatment of colon carcinoma CC531, implanted in liver of Wag/Rij rats. The NecrA in the tumor and surrounding normal liver tissues depended on the absorbed dose of PI and increased with its increase (p < 0.001). The authors noted that application of an exposure dose of 800 J allows to achieve complete regression of tumors in 66.7% of animals. The authors have proved the fact that the use of iPDT allows achieving a good therapeutic results with a minimal risk of damage to normal liver tissues. Rovers et al. [14] performed iPDT (λ = 652 nm, 0.1 W, 15 J) with intravenously administered of mTHPC at a dose 0.3 mg/kg of body weight on Wag/Rij rats with metastatic liver orthotopic model CC531 colon adenocarcinoma. Authors reported that iPDT resulted in complete tumor remission in 87% of animals [14].

van Duijnhoven et al. [17] investigated effects of iPDT (λ = 652 nm, 200 mW, 16 J/cm²) with mTHPC (0.3 mg/kg) on liver metastases of orthotopic model of CC531 colon adenocarcinoma. Authors reported that iPDT was effective in causing photodynamically-induced photochemical Necr of tumors, but it did not affect the growth rate of non-luminated tumors in the liver. Immunological staining...
of tumors showed natural killer cells to be significantly lower in tumors treated with interstitial PI than in control tumors (p < 0.05). Otake et al. [15] published the results of their study on the efficacy of i PDT (λ = 630 nm, 160 mW, 47–90 J/cm²) with 5-ALA at a dose of 500 mg/kg administered intravenously 3 h before PI in the treatment of chemically induced hepatocellular carcinoma in rats. The authors concluded that in all treated tumors, Necr was evident at 24 h after 5ALA-iPDT [15]. Several teams of scientists made successful attempts for the clinical testing of i PDT for patients with unresectable primary and metastatic malignant liver tumors [6, 7]. Vogl et al. [7] presented the results of several phase I clinical trials based on the use of i PDT in the treatment of the liver metastases. In the first study authors reported about 5 patients with liver metastasis of colorectal cancer treated with PS SQN 400 (mTHPBC) at a dose of 6 mg/kg and PI (λ = 740 nm; 60 J/cm²) 120 h after SQN 400 administration. Depending on the location and size of lesions, the authors have used from 4 to 7 special fibers installed in the tumor site under the center CT control. After 3 months in all cases CT study recorded photodynamically-induced Necr with no evidence of damage to the normal liver parenchyma, and after 6 months in 50% of the metastases continued growth was not revealed [7]. In the second study, the authors have included 4 patients with liver metastasis of colorectal cancer (n = 3) and melanoma (n = 1). PS LS 11 (Talaporfin sodium) was injected intravenously at a standard dose of 40.0 mg/m². At 4 h post-injection, a tumor was photoradiated with a “PDT laser” with 25 mm optical fibers (λ = 630 nm; 400 mW/cm²; 100 J/cm²). The average size of Necr, confirmed the results of CT studies, was 14 mm. At the control observation after 6 weeks in 2 cases complete regression of tumor was recorded [7].

However, a moderate number of studies in this field points on the need for further research to determine antitumor efficacy of i PDT in the treatment of this pathology. In further experimental studies, we plan to study the antitumor efficacy of i PDT in the treatment of other tumor strains. If positive results will be obtained, we will be able to recommend the developed method for approbation in clinical oncology.

REFERENCES


